’ facility in Antwerp, Belgium has completed upgrades for the manufacture of Niacin (nicotinic acid) for pharmaceutical use. For 30 years the plant has produced Niacin USP and Niacinamide for human food applications and agricultural needs. Vertellus upgraded the facility to meet cGMP guidelines for the manufacture of an API and it has been inspected and approved by the U.S. FDA. Major changes include validation of all critical equipment, manufacturing processes, analytical methodology and data collection systems.
"We are very excited to broaden our market capabilities to include pharmaceutical use for Niacin," said Bentley Park, president of Vertellus Agriculture & Nutrition Specialties LLC. "Among other applications, Niacin increasingly is used as a critical ingredient in drugs that help improve cardiovascular health by increasing good cholesterol levels. We can now provide another source and more options for pharmaceutical companies making those life-saving drugs."